---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-026748"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T06:16:14.974372+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FibroGen's pamrevlumab fails Phase 3 DMD study in non-ambulatory patients; primary endpoint not met

## Summary
- Phase 3 LELANTOS-1 study of pamrevlumab in non-ambulatory DMD patients did not meet primary endpoint (PUL 2.0 score at week 52).
- Pamrevlumab was generally safe and well tolerated; most adverse events were mild or moderate.
- Topline results from LELANTOS-2 Phase 3 study in ambulatory DMD patients expected in Q3 2023.
- CEO Enrique Conterno expressed disappointment and thanked patients, caregivers, and investigators.

## SEC filing metadata
- accession: 0000950170-23-026748
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017023026748/0000950170-23-026748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017023026748/fgen-20230607.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-026748
- JSON: https://secwatch.observer/filing/0000950170-23-026748.json
- Plain text: https://secwatch.observer/filing/0000950170-23-026748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.